Investigational drug · Phase 3
LM-108
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Advanced Pancreatic Cancer, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
10
Any phase or sponsor naming "LM-108"
First trial start
2022
Mar 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LM-108", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Advanced Pancreatic Cancer
- Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "LM-108" as an intervention, largest first.
- LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
LaNova Medicines LimitedIndustry
NCT07362186 · 400 participants (planned) · Start Apr 30, 2026 · Primary completion Aug 17, 2028
Drug: LM-108 in combination with Toripalimab; Paclitaxel injection intravenous infusion · For: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Sites: Beijing, China
- A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsActive, not recruiting
LaNova Medicines LimitedIndustry
NCT05518045 · 392 participants (planned) · Start Aug 26, 2022 · Primary completion Oct 31, 2026
Drug: LM-108; Toripalimab · For: Advanced Solid Tumor
Sites: Beijing, China
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialPivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06620822 · 296 participants (planned) · Start Sep 30, 2024 · Primary completion Sep 30, 2026
Drug: IBI363; LM-108+Sintilimab and 2 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China
- Clinical Studies for the Treatment of Advanced Solid TumorsPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06825494 · 194 participants (planned) · Start Apr 8, 2025 · Primary completion Mar 2026
Drug: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine; Tislelizumab+Oxaliplatin+Capecitabine and 3 more · For: Advanced Solid Tumor
Sites: Hefei, China; Beijing, China; Fuzhou, China · 32 sites in all
- A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid TumoursNot yet recruiting
LaNova Medicines LimitedIndustry
NCT06873854 · 84 participants (planned) · Start Mar 26, 2025 · Primary completion Jan 26, 2028
Drug: LM-108; Toripalimab · For: Advanced Solid Tumor
Sites: Beijing, China
LaNova Australia Pty LimitedIndustry
NCT05199753 · 78 participants · Start Mar 16, 2022 · Primary completion Dec 31, 2024
Drug: LM-108; An Anti-PD-1 Antibody · For: Advanced Solid Tumor
Sites: Sydney, Australia; Birtinya, Australia; South Brisbane, Australia · 6 sites in all
Fudan UniversityAcademic, hospital or other
NCT06387628 · 74 participants (planned) · Start Jul 10, 2024 · Primary completion Apr 1, 2026
Drug: LM-108; Toripalimab and 2 more · For: TNBC - Triple-Negative Breast Cancer
Sites: Shanghai, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06821503 · 72 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 2027
Drug: LM-108 injection; Penpulimab injection and 2 more · For: Advanced Pancreatic Cancer
Sites: Beijing, China; Chongqing, China; Harbin, China · 16 sites in all
- LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus unknown
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06479759 · 50 participants (planned) · Start Jan 12, 2024 · Primary completion Jun 12, 2025
Drug: LM-108 antibody and sintilimab; LM-108 antibody and sintilimab and chemotherapy · For: NSCLC; PD-1
Sites: Shanghai, China
LaNova Medicines LimitedIndustry
NCT05255484 · 24 participants · Start May 26, 2022 · Primary completion Oct 6, 2023
Drug: LM-108; An Anti-PD-1 Antibody · For: Advanced Solid Tumor
Sites: Ocala, Florida; Indianapolis, Indiana; Canton, Ohio · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells.
Chen P, Wang H, Tang Z, et al. · J Thorac Oncol 2025
- Characterization of TistH, a multifunctional peptide from the scorpion Tityus stigmurus: Structure, cytotoxicity and antimicrobial activity.
Machado RJ, Estrela AB, Nascimento AK, et al. · Toxicon 2016
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.